NCT04136873View on ClinicalTrials.gov

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

May 7, 2021

Study Completion Date

June 3, 2021

Conditions
Schizophrenia
Interventions
DRUG

CVL-231

CVL-231

DRUG

Matching Placebo

Placebo matching CVL-231

Trial Locations (5)

72211

Woodlands International Research Group, Little Rock

72712

Pillar Clinical Research, Bentonville

90806

Collaborative Neuroscience Network, LLC, Long Beach

91945

Synergy San Diego, Lemon Grove

08053

Hassman Research Institute, Marlton

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT04136873 - A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter